SantosJSArajoICSMartinsPCRoyerAFBCafMBAndradeMAet al
Most Common Adverse Events Key Observations: Gastrointestinal adverse events are dose-dependent and most pronounced during dose escalation Symptoms typically peak within the first 4-8 weeks and diminish with continued treatment as tolerance develops Slow titration (4-week intervals) significantly reduces the incidence and severity of GI events Most adverse events classified as mild to moderate in severity [9] Discontinuation Rates 7.3% Placebo discontinuation rate [9] 15.8% Cagrilintide 2.4 mg (optimal dose) [9] 24.5% Cagrilintide 4.5 mg (high dose) [9] The majority of discontinuations due to adverse events occurred during the titration phase, with GI symptoms (nausea, vomiting) being the primary reasons
In summary, the flavonoid pathway in tomato is a well-defined genetic and enzymatic network
Wang X, Zhang J, Wang S, Song Z, Sun H, Wu F, et al
Majidinia M, Reiter RJ, Shakouri SK, et al